A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients

K. Zarogoulidis, A. Xafenias, P. Panousis, T. Kontakiotis, D. Iakovidis, D. Patakas (Thessaloniki, Greece)

Source: Annual Congress 2002 - Thoracic oncology: clinical management
Session: Thoracic oncology: clinical management
Session type: Poster Discussion
Number: 1189
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Zarogoulidis, A. Xafenias, P. Panousis, T. Kontakiotis, D. Iakovidis, D. Patakas (Thessaloniki, Greece). A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients. Eur Respir J 2002; 20: Suppl. 38, 1189

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006

Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study
Source: Eur Respir J 2003; 22: Suppl. 45, 28s
Year: 2003

Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009

Phase II trial of docetaxel and carboplatin in previously untreated patients with non-small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001

Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial
Source: Eur Respir J 2002; 20: Suppl. 38, 187s
Year: 2002

A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 781s
Year: 2006

Weekly chemotherapy with cisplatin and paclitaxel in inoperable advanced non-small cell lung cancer: an extended phase II study
Source: Eur Respir J 2005; 26: Suppl. 49, 12s
Year: 2005

First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019
Year: 2020



Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007


A phase I trial of combined carboplatin and topotecan as 2nd line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 30s
Year: 2003

Docetaxel in combination with carboplatin in the treatment of Stage IIIb and IV non-small cell lung cancer patients. A Phase II study
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005

A three-arms phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 318s
Year: 2001

Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004

Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005


Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002

A randomised prospective trial of concurrent chemoradiotherapy (CCRT) with cisplatin and paclitaxel or docetaxel or gemcitabine in stage IIIB nonsmall cell lung cancer
Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer
Year: 2009



Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC)
Source: Eur Respir J 2007; 30: Suppl. 51, 241s
Year: 2007

A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2004; 24: Suppl. 48, 303s
Year: 2004

A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016